Focusing on patients with multiple myeloma who receive GPRC5D-targeted therapy, Beth Faiman, CNP, PhD, discusses how long-term treatment impacts patients’ tolerance to adverse events.
Stay up to date on recent advances in the multidisciplinary approach to cancer.